Literature DB >> 10661508

Azotemia (48 h) decreases the risk of brain damage in rats after correction of chronic hyponatremia.

A Soupart1, R Penninckx, A Stenuit, G Decaux.   

Abstract

Brain myelinolysis complicates excessive correction of chronic hyponatremia in man. Myelinolysis appear in rats for correction levels deltaSNa) > 20 mEq/l/24 h. We previously showed in rats that when chronic hyponatremia was corrected with urea, the incidence and the severity of brain lesions were significantly reduced compared to hypertonic saline. In man, hyponatremia is frequently associated with azotemia and hemo-dialysis usually corrects rapidly the serum sodium (SNa) but only few patients apparently develop demyelination. We hypothesize that uremic state protects brain against myelinolysis. This hypothesis was evaluated in rats developing azotemia by administration of mercuric chloride (HgCl2, 1.5 mg/kg). Severe (SNa < 120 mEq/l) hyponatremia (3 days) was induced by S.C. AVP and i.p. 2.5% D-glucose for 3 days. HgCl2 was injected on day 2. Hyponatremia was corrected on day 4 by i.p. injections of 5% NaCl in order to obtain a correction level largely above the toxic threshold for brain (deltaSNA approximately 30 mEq/l/24 h). Surviving rats were decapitated on day 10 for brain analysis. In the group with renal failure (Group I, n = 15, urea 59 mmol/l) the outcome was remarkably favourable with only three rats (3/15) dying before day 10 and only one of them (1/3) presenting myelinolysis-related neurologic symptoms. The 12 other rats (80%) survived in Group I without symptoms and brain analysis was normal in all of them despite large correction level (deltaSNa: 32 mEq/l/24 h). On the contrary in nine rats in which HgCl, did not produce significant azotemia (control 1, n = 9, urea: 11 mmol/l), all the rats developed severe neurologic symptoms and eight of them died before day 10. Similar catastrophic outcome was observed in the non-azotemic controls (control 2, no HgCl2 administration, n = 15, urea: 5 mmol/l). All of them developed myelinolysis-related neurologic symptoms and only four of them survived with severe brain lesions (survival 12/15 in Group I vs. 5/24 in pooled controls 1 and 2, p < 0.001). In conclusion, we showed for the first time that chronic hyponatremic rats with azotemia (48 h) tolerated large increases in SNa (approximately 30 mEq/l/24 h) without significant brain damage.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10661508     DOI: 10.1016/s0006-8993(99)02259-3

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  14 in total

1.  Apparent diffusion coefficient map based on diffusion-weighted magnetic resonance imaging is useful in diagnosing the brainstem variant of reversible posterior leukoencephalopathy syndrome with uremia.

Authors:  Kenichi Katano; Yasushi Kakuchi; Akikatsu Nakashima; Katsuyuki Nakahama; Mitsuhiro Kawano
Journal:  Clin Exp Nephrol       Date:  2010-05-25       Impact factor: 2.801

2.  Central pontine myelinolysis: historical and mechanistic considerations.

Authors:  Michael D Norenberg
Journal:  Metab Brain Dis       Date:  2010-02-25       Impact factor: 3.584

3.  Osmotic Stress-Induced Defective Glial Proteostasis Contributes to Brain Demyelination after Hyponatremia Treatment.

Authors:  Fabrice Gankam-Kengne; Bruno S Couturier; Alain Soupart; Jean Pierre Brion; Guy Decaux
Journal:  J Am Soc Nephrol       Date:  2017-01-25       Impact factor: 10.121

4.  Osmotic Demyelination Syndrome following Correction of Hyponatremia by ≤10 mEq/L per Day.

Authors:  Srijan Tandukar; Richard H Sterns; Helbert Rondon-Berrios
Journal:  Kidney360       Date:  2021-07-08

Review 5.  Preventing neurological complications from dysnatremias in children.

Authors:  Michael L Moritz; J Carlos Ayus
Journal:  Pediatr Nephrol       Date:  2005-08-04       Impact factor: 3.714

6.  Management of hyponatremia in various clinical situations.

Authors:  Michael L Moritz; Juan C Ayus
Journal:  Curr Treat Options Neurol       Date:  2014-09       Impact factor: 3.598

Review 7.  Dysnatremias in patients with kidney disease.

Authors:  Sara Combs; Tomas Berl
Journal:  Am J Kidney Dis       Date:  2013-11-14       Impact factor: 8.860

8.  Treatment of euvolemic hyponatremia in the intensive care unit by urea.

Authors:  Guy Decaux; Caroline Andres; Fabrice Gankam Kengne; Alain Soupart
Journal:  Crit Care       Date:  2010-10-14       Impact factor: 9.097

Review 9.  Clinical review: use of renal replacement therapies in special groups of ICU patients.

Authors:  Eric A J Hoste; Annemieke Dhondt
Journal:  Crit Care       Date:  2012-01-19       Impact factor: 9.097

10.  Actual Therapeutic Indication of an Old Drug: Urea for Treatment of Severely Symptomatic and Mild Chronic Hyponatremia Related to SIADH.

Authors:  Guy Decaux; Fabrice Gankam Kengne; Bruno Couturier; Frédéric Vandergheynst; Wim Musch; Alain Soupart
Journal:  J Clin Med       Date:  2014-09-18       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.